Imatinib Mesylate (IM) Resistant ALL Cell Line (BV173/E255K)
Human acute lymphoblastic leukemia (ALL) cell line BV173, that exhibits Imatinib mesylate (IM) resistance due to the expression of BCR/ABL kinase harboring the E255K mutation.
Highlights:
- Isolated from peripheral blood
- BV173 human leukemia cell line that expresses BCR/ABL kinase harboring the E255K mutation
- Useful research tool for studying IM resistance and potentially resistance to other tyrosine kinase (Bcr/Abl) inhibitors
- Capable for in vivo studies involving immunocompromised mice
Imatinib mesylate (IM) represents a primary treatment option for individuals with chronic myelogenous leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). However, patients often acquire IM resistance via mutations in the Bcr/Abl kinase domain, which reportedly account for 50-90% of acquired resistance. The E255K along with T315I mutations are the most two frequently observed in IM-resistant patients.
From the laboratories of Steven Grant, MD, Virginia Commonwealth University.
Part of The Investigator's Annexe program.
Human acute lymphoblastic leukemia (ALL) cell line BV173, that exhibits Imatinib mesylate (IM) resistance due to the expression of BCR/ABL kinase harboring the E255K mutation.
Highlights:
- Isolated from peripheral blood
- BV173 human leukemia cell line that expresses BCR/ABL kinase harboring the E255K mutation
- Useful research tool for studying IM resistance and potentially resistance to other tyrosine kinase (Bcr/Abl) inhibitors
- Capable for in vivo studies involving immunocompromised mice
Imatinib mesylate (IM) represents a primary treatment option for individuals with chronic myelogenous leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). However, patients often acquire IM resistance via mutations in the Bcr/Abl kinase domain, which reportedly account for 50-90% of acquired resistance. The E255K along with T315I mutations are the most two frequently observed in IM-resistant patients.
From the laboratories of Steven Grant, MD, Virginia Commonwealth University.
Part of The Investigator's Annexe program.
| Product Type: | Cell Line |
| Name: | BV173/E255K |
| Cell Type: | B cell precursor leukemia (ALL) |
| Accession ID: | CVCL_5K95 |
| Morphology: | Round to elongated, single cells in suspension |
| Source: | BV173 cell line |
| Organism: | Human peripheral blood |
| Biosafety Level: | BSL2 |
| Subculturing: | Seed out at density 0.3-1 x 106 cells/ml; split saturated culture 1:2 to 1:3 every 2-3 days |
| Growth Conditions: | 80-90 % RPMI 1640 + 10-20% FBS |
| Cryopreservation: | 90% FBS + 10% DMSO |
| Storage: | Liquid nitrogen |
| Shipped: | Dry ice |
- Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res. 2011 May 15;17(10):3219-32.
If you publish research with this product, please let us know so we can cite your paper.
